X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Natco Pharma with Strides Arcolab - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

NATCO PHARMA vs STRIDES SHASUN LTD - Comparison Results

STRIDES SHASUN LTD 
   Change

Strides Arcolab is an Indian pharmaceutical company headquartered at Bangalore. The company is primarily involved in two businesses notably the pharma business and the specialized sterile products business branded as Agila. This segment focuses large... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    NATCO PHARMA STRIDES SHASUN LTD NATCO PHARMA/
STRIDES SHASUN LTD
 
P/E (TTM) x 23.7 13.7 172.6% View Chart
P/BV x 18.0 1.6 1,128.0% View Chart
Dividend Yield % 0.6 0.6 102.4%  

Financials

 NATCO PHARMA   STRIDES SHASUN LTD
EQUITY SHARE DATA
    NATCO PHARMA
Mar-14
STRIDES SHASUN LTD
Mar-17
NATCO PHARMA/
STRIDES SHASUN LTD
5-Yr Chart
Click to enlarge
High Rs8771,275 68.8%   
Low Rs424918 46.1%   
Sales per share (Unadj.) Rs223.4389.6 57.4%  
Earnings per share (Unadj.) Rs31.128.0 111.1%  
Cash flow per share (Unadj.) Rs40.348.9 82.4%  
Dividends per share (Unadj.) Rs5.004.50 111.1%  
Dividend yield (eoy) %0.80.4 187.3%  
Book value per share (Unadj.) Rs219.5303.1 72.4%  
Shares outstanding (eoy) m33.0789.42 37.0%   
Bonus/Rights/Conversions PAESOP-  
Price / Sales ratio x2.92.8 103.4%   
Avg P/E ratio x20.939.2 53.4%  
P/CF ratio (eoy) x16.122.4 72.0%  
Price / Book Value ratio x3.03.6 81.9%  
Dividend payout %16.116.1 100.0%   
Avg Mkt Cap Rs m21,50498,036 21.9%   
No. of employees `000NA5.8 0.0%   
Total wages/salary Rs m1,1285,881 19.2%   
Avg. sales/employee Rs ThNM6,005.9-  
Avg. wages/employee Rs ThNM1,014.0-  
Avg. net profit/employee Rs ThNM431.2-  
INCOME DATA
Net Sales Rs m7,38934,834 21.2%  
Other income Rs m1671,686 9.9%   
Total revenues Rs m7,55636,520 20.7%   
Gross profit Rs m1,7936,428 27.9%  
Depreciation Rs m3041,872 16.3%   
Interest Rs m3662,269 16.1%   
Profit before tax Rs m1,2903,973 32.5%   
Minority Interest Rs m460-   
Prior Period Items Rs m04 0.0%   
Extraordinary Inc (Exp) Rs m0-1,006 0.0%   
Tax Rs m309470 65.7%   
Profit after tax Rs m1,0272,501 41.1%  
Gross profit margin %24.318.5 131.5%  
Effective tax rate %23.911.8 202.3%   
Net profit margin %13.97.2 193.7%  
BALANCE SHEET DATA
Current assets Rs m3,68138,165 9.6%   
Current liabilities Rs m3,12330,402 10.3%   
Net working cap to sales %7.622.3 33.9%  
Current ratio x1.21.3 93.9%  
Inventory Days Days8977 115.7%  
Debtors Days Days59104 56.2%  
Net fixed assets Rs m7,68537,639 20.4%   
Share capital Rs m331894 37.0%   
"Free" reserves Rs m6,67026,210 25.4%   
Net worth Rs m7,25927,105 26.8%   
Long term debt Rs m95516,377 5.8%   
Total assets Rs m11,95781,168 14.7%  
Interest coverage x4.52.8 164.4%   
Debt to equity ratio x0.10.6 21.8%  
Sales to assets ratio x0.60.4 144.0%   
Return on assets %11.75.9 198.3%  
Return on equity %14.29.2 153.4%  
Return on capital %20.712.1 172.0%  
Exports to sales %39.40-   
Imports to sales %5.70-   
Exports (fob) Rs m2,908NA-   
Imports (cif) Rs m421NA-   
Fx inflow Rs m3,44513,465 25.6%   
Fx outflow Rs m7034,076 17.2%   
Net fx Rs m2,7439,389 29.2%   
CASH FLOW
From Operations Rs m1,4402,881 50.0%  
From Investments Rs m-1,089-7,051 15.4%  
From Financial Activity Rs m-3533,382 -10.4%  
Net Cashflow Rs m-1-788 0.2%  

Share Holding

Indian Promoters % 52.0 27.7 187.9%  
Foreign collaborators % 1.5 0.0 -  
Indian inst/Mut Fund % 7.8 37.8 20.7%  
FIIs % 16.6 8.6 193.4%  
ADR/GDR % 0.0 0.0 -  
Free float % 26.0 25.9 100.4%  
Shareholders   25,395 56,241 45.2%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare NATCO PHARMA With:   PIRAMAL ENTERPRISES  NOVARTIS  PANACEA BIOTECH  DR. REDDYS LAB  GSK PHARMA  

Compare NATCO PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Finishes Marginally Lower; Capital Goods & Realty Stocks Fall(Closing)

Indian share markets witnessed selling pressure in the final hour of trade to finish just below the dotted line. At the closing bell, the BSE Sensex closed lower by 71 points.

Related Views on News

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

Follow India's Super Investors to Make Big Money in the Market Crash(The 5 Minute Wrapup)

Feb 8, 2018

Has the sell-off in the markets left India's super investors unduly worried?

The Era of Easy Money is Coming to an End. What Happens Now?(Vivek Kaul's Diary)

Feb 9, 2018

The easy money policy of the Federal Reserve of the United States, which drove up stock markets all over the world, is ending, with the Federal Reserve looking to shrink its balance sheet.

The Markets Want Your Money. Don't Give It to Them.(Smart Contrarian)

Feb 9, 2018

MFs are having a gala time taking money from over-eager investors and funneling it into equities. Smart investors, though, know better than to do that.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

Rising Dominance of Mutual Funds(Chart Of The Day)

Feb 8, 2018

Domestic money flow into Indian equities surpassed foreign fund flows in the recent years. But will it continue in volatile market?

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

NATCO PHARMA SHARE PRICE


Feb 20, 2018 (Close)

TRACK NATCO PHARMA

  • Track your investment in NATCO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

NATCO PHARMA 8-QTR ANALYSIS

COMPARE NATCO PHARMA WITH

MARKET STATS